A Multi-Center Trial of the ProLung Test™

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Fresh Medical Laboratories
Sponsor:
Collaborators:
Huntsman Cancer Institute
University of California, Los Angeles
Henry Ford Health System
University of California, San Diego
Intermountain Health Care, Inc.
M.D. Anderson Cancer Center
Greater Baltimore Medical Center
University of Tennessee Medical Center
Information provided by (Responsible Party):
Fresh Medical Laboratories
ClinicalTrials.gov Identifier:
NCT01566682
First received: March 27, 2012
Last updated: June 13, 2016
Last verified: June 2016
  Purpose

The primary Study hypothesis is that the ProLung Test will demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. A statistically significant result will indicate that patients with a high ProLung Test result have a greater risk of developing lung cancer than patients with a low test result.

There are three Specific Aims of this study:

  1. Optimize and confirm the stability of the ProLung Test risk-stratification algorithm in patients with a diagnosis.
  2. Externally validate the efficacy of the ProLung Test risk-stratification algorithm by comparing the test result to the conclusive patient diagnosis.
  3. Assess the safety and tolerability of the ProLung Test procedures.

Study Design This Study consists of two distinct phases, Stabilization and Validation. The Study will collect data from multiple sites (3 to 12), and each site may enroll patients and collect data for the Stabilization and Validation Phases with a minimum of three sites for the Validation Phase.


Condition
Solitary Pulmonary Nodule
Multiple Pulmonary Nodules

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Multi-Center Trial of the ProLung Test™ (Transthoracic Bioconductance Measurement) as an Adjunct to CT Chest Scans for the Risk Stratification of Patients With Pulmonary Lesions Suspicious for Lung Cancer

Resource links provided by NLM:


Further study details as provided by Fresh Medical Laboratories:

Primary Outcome Measures:
  • Clinical Efficacy in the risk stratification of patients with indeterminate lesions [ Time Frame: The ProLung Test will be performed within 60 days of a CT Scan that identifies a lung lesion suspicious for lung cancer and evaluated once a patient diagnosis is obtained. ] [ Designated as safety issue: Yes ]
    Demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer.


Estimated Enrollment: 300
Study Start Date: October 2012
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts
Indeterminate Pulmonary Lesions
Patients with Pulmonary Lesions as seen by CT

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects with pulmonary lesions suspicious for lung cancer
Criteria

Inclusion Criteria:

Subjects who meet all of the following criteria may be enrolled in this Study:

  1. Subject is male or female, age 18 or older.
  2. Subject has undergone CT scan of the lung(s) that indicates one or more nodules or lesions suspicious for lung cancer.
  3. Subject's pulmonary nodule or lesion is greater than 4mm. Size is determined by the largest nodule or lesion dimension identified from CT imaging.
  4. Subject meets one or more of the following conditions:

    • indicated for a tissue biopsy of the lung
    • indicated for surgical resection of the lung
    • being followed by CT for nodule growth within a 1-year time frame*

      • subject must receive at least one follow-up CT by their 1-year enrollment anniversary or within 60 days after their 1-year enrollment anniversary to continue in the Study.
  5. Subject must be able to receive a ProLung Test

    • within 60 days of abnormal CT (Inclusion Criterion 2 & 3)
    • within 60 days prior to the tissue biopsy or surgical resection (Inclusion Criterion 4).
  6. Subject is capable of understanding and agreeing to fulfill the requirements of this Protocol.
  7. Subject has signed the IRB/IEC approved Informed Consent Form ("ICF").

Exclusion Criteria

The following criteria will disqualify a subject from enrollment into this Study:

  1. Subject has an implanted electronic device in the chest.
  2. Subject receiving therapy for suspected chest infection such as fungal infection or tuberculosis.
  3. Subject with diagnosed malignancy other than lung cancer who has 2 or more suspicious pulmonary nodules.
  4. Subject has received an invasive medical or surgical procedure within the thoracic cavity within 30 days prior to the ProLung Test or within the previous 14 days for a bronchoscopic procedure.
  5. Subject presents with an anomalous physical or anatomical condition that precludes ProLung Test measurement.
  6. Subject will have undergone unusually strenuous exercise within 24 hours.
  7. Subject who has significant systemic diseases such as uncontrolled diabetes, advanced heart failure, or a recent myocardial infarction, or other medical condition such as severe morbid obesity that in the judgment of the Principal Investigator would make him/her unsuitable for the Study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01566682

Contacts
Contact: Michael A Garff, BS, MBA 8012049625 mag@prolung.com

Locations
United States, California
UCLA Medical Center Recruiting
LA, California, United States, 90024
Contact: John Dermand    310-206-0396    jdermand@mednet.ucla.edu   
Sub-Investigator: Denise Aberle, MD         
Sub-Investigator: Fereidoun Abtin, MD         
Principal Investigator: Igor Barjaktarevic         
UCSD Medical Center Recruiting
San Diego, California, United States, 92103
Contact: Anne Powers, RN, MSN, FNP    858-449-7218    atpowers@ucsd.edu   
Contact: Laura Peluso, RN    619-543-5840    lpeluso@ucsd.edu   
Principal Investigator: Samir Makani, MD         
United States, Maryland
Greater Baltimore Medical Center Recruiting
Townson, Maryland, United States, 21204
Contact: Garnitha Ferguson    443-849-8058    gferfuso@gbmc.org   
Contact: Troy Gogoll    443-849-3592    Tgogoll@gbmc.org   
Principal Investigator: Rex Yung, MD         
United States, Michigan
Henry Ford Medical Center Recruiting
Detroit, Michigan, United States, 48202
Contact: Roel Almario, R.N., B.S.N.    313-916-3558    ralmari1@hfhs.org   
Principal Investigator: Michael Simoff, MD         
United States, Tennessee
University of Tennessee Active, not recruiting
Knoxville, Tennessee, United States, 37920
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Brian Tian    713-745-2645    XTian@mdanderson.org   
Contact: Laila Noor    713-745-2645    LZNoor@mdanderson.org   
United States, Utah
Intermountain Healthcare Recruiting
Murray, Utah, United States, 84157
Contact: Mardee Merrill    801-507-4608    mardee.merrill@imail.org   
Principal Investigator: Denitza Blagev, MD         
Huntsman Cancer Institute Recruiting
SLC, Utah, United States, 84112
Contact: Natlie Graves    801-213-5672    natalie.graves@hci.utah.edu   
Contact: Stephen Bergquist    801-587-4284    stephen.bergquist@hci.utah.edu   
Principal Investigator: Chakravarthy Reddy, MD         
Sponsors and Collaborators
Fresh Medical Laboratories
Huntsman Cancer Institute
University of California, Los Angeles
Henry Ford Health System
University of California, San Diego
Intermountain Health Care, Inc.
M.D. Anderson Cancer Center
Greater Baltimore Medical Center
University of Tennessee Medical Center
Investigators
Principal Investigator: Fereidoun Abtin, MD UCLA Radiological Sciences Section of Thoracic Imaging
Principal Investigator: Chakravarthy Reddy, MD Huntsman Cancer Institute
Principal Investigator: Michael Simoff, MD Henry Ford Health System
  More Information

Responsible Party: Fresh Medical Laboratories
ClinicalTrials.gov Identifier: NCT01566682     History of Changes
Other Study ID Numbers: PL-208 
Study First Received: March 27, 2012
Last Updated: June 13, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Fresh Medical Laboratories:
Lung Lesion
Lung Mass
Lung Nodule
Lung Cancer
Low-Dose CT
CT
Diagnostic
Evaluation
Bioconductance
ProLung

Additional relevant MeSH terms:
Multiple Pulmonary Nodules
Solitary Pulmonary Nodule
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 26, 2016